Preclinical Evaluation of 1,2-Diamino-4,5-Dibromobenzene in Genetically Engineered Mouse Models of Pancreatic Cancer

Preclinical Evaluation of 1,2-Diamino-4,5-Dibromobenzene in Genetically Engineered Mouse Models of Pancreatic Cancer

<b>Background:</b> Pancreatic ductal adenocarcinoma (PDAC) is highly resistant to standard chemo- and radiotherapy. Recently, a new class of non-platinum-based halogenated molecules (called FMD compounds) was discovered that selectively kills cancer cells. Here, we investigate the potent...

Full description

Bibliographic Details
Main Authors: Robert G. Goetze, Soeren M. Buchholz, Ning Ou, Qinrong Zhang, Shilpa Patil, Markus Schirmer, Shiv K. Singh, Volker Ellenrieder, Elisabeth Hessmann, Qing-Bin Lu, Albrecht Neesse
Format: Article
Language:English
Published: MDPI AG 2019-06-01
Series:Cells
Subjects:
1,2-Diamino-4,5-dibromobenzene
femtomedicine compounds
pancreatic cancer
GEMMs
chemoresistance
radiation therapy
radiosensitizer
Online Access:https://www.mdpi.com/2073-4409/8/6/563

Internet

https://www.mdpi.com/2073-4409/8/6/563

Similar Items